Sherlock Biosciences
Main focus: Development of novel Cas-enzymes for diagnostics
Company stage: Commercial (diagnostics), pre-clinical (therapeutics)
Diseases: COVID-19 (diagnostics)
Genome editing tool: CRISPR-Cas12a, CRISPR-Cas12b, CRISPR-Cas13.
Funding stage: Private
Location: Cambridge, MA, USA
Website: https://sherlock.bio/
Partners: Tolo Biotech
Sherlock Biosciences is a CRISPR diagnostics company. The company deploys its SHERLOCK™- and INSPECTR™-platforms that are based on novel Cas-enzymes, and so far, it has commercialised a novel CRISPR-based SARS-CoV-2 detection kit. The company is co-founded by Feng Zhang, who also co-founded Arbor Biotechnologies and Beam Therapeutics.